Atossa Genetics (NASDAQ:ATOS) Announces Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Atossa Genetics (NASDAQ:ATOS) released its quarterly earnings data on Friday. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.12), FiscalAI reports.

Atossa Genetics Price Performance

ATOS opened at $5.60 on Friday. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35. The stock has a market capitalization of $48.22 million, a price-to-earnings ratio of -1.56 and a beta of 1.25. The business has a fifty day moving average price of $5.18 and a 200 day moving average price of $8.28.

Analyst Ratings Changes

ATOS has been the subject of several recent analyst reports. Ascendiant Capital Markets cut their price objective on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, April 10th. HC Wainwright raised their price objective on shares of Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $36.33.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Atossa Genetics by 4.2% in the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after acquiring an additional 245,717 shares during the last quarter. Ameriprise Financial Inc. purchased a new position in Atossa Genetics in the second quarter worth approximately $2,468,000. Renaissance Technologies LLC lifted its stake in Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after acquiring an additional 514,175 shares during the last quarter. Geode Capital Management LLC lifted its stake in Atossa Genetics by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after acquiring an additional 9,627 shares during the last quarter. Finally, State Street Corp lifted its stake in Atossa Genetics by 31.2% in the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after acquiring an additional 141,990 shares during the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.